2 ASX AI shares that could be set to soar in 2024 and beyond

Analysts think these shares with AI exposure are top buys and destined for strong growth.

| More on:
A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The share market has been getting very excited about the artificial intelligence (AI) megatrend this year.

And rightly so. It's no exaggeration to say that AI is going to change the world.

We've only really had a small taste of this in the last few years but expect things to accelerate as AI continues to improve and more money is invested in the space.

The good news for investors is that there are ways to gain exposure to AI with ASX shares.

And I don't mean with supposed AI shares like Brainchip Holdings Ltd (ASX: BRN), which has promised the world and delivered nothing in a market dominated by a US$3 trillion behemoth.

I mean with genuine industry leaders that are leveraging AI to cement their position and drive long-term growth. Let's take a look at two:

Pro Medicus Limited (ASX: PME)

The first ASX AI share to look at is health imaging technology company Pro Medicus,

Goldman Sachs recently spoke about how the company's AI revenues could grow from a small percentage of its overall sales into something significant in the future. It said:

AI opens an incremental US$620mn TAM today (growing at a +34.7% CAGR) with radiology receiving the majority (c.80%) of recent FDA AI algorithm clearance. We believe PME is well positioned to take share as the incumbent viewing platform across many large, and likely early adopters of new technology.

PME is generating revenue from its Visage breast density AI algorithm (developed via a partnership with Yale) today, and we see the potential value for AI to be significant with adoption driven by improved accuracy and clinical outcomes. We forecast AI to comprise 9% of PME's revenue by FY30E (from <1% in FY25E), with upside if PME achieves faster AI attach penetration, higher price per scan, and a greater proportion of algorithms developed in-house where no royalties are paid to a partner.

Goldman has a buy rating and $136.00 price target on its shares.

NextDC Ltd (ASX: NXT)

Another ASX AI share to look at is data centre operator NextDC. While it isn't necessarily offering AI services, it is servicing the huge data centre demand for capacity that AI needs to function.

In April, Goldman Sachs commented on this. It said:

NextDC believes AI is driving global data centre growth from 15% to 19% with Australia and broader APAC remaining well-positioned for growth and the fastest growing region. AI is increasing average power density racks (kW/Rack) growing 2.5x to c80-100kW. NXT are seeing demand pipeline for singular deals in the vicinity of 50-100MW and see market growth accelerating. AI demand is also stemming from a 40%/60% mix from inference/training, with upside for inference to reach 70%.

The broker currently has a buy rating and $18.59 price target on its shares. Though, it is worth noting that other brokers are even more bullish. For example, Morgan Stanley has an overweight rating and $20.00 price target.

Motley Fool contributor James Mickleboro has positions in Nextdc and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

One girl leapfrogs over her friend's back.
Technology Shares

This ASX 200 tech stock would have doubled your money in a year. Is it too late to buy now?

After more than doubling in a year, here’s what Macquarie expects next for this soaring ASX 200 tech stock.

Read more »

Two brokers analysing stocks.
Technology Shares

What are top brokers saying about Xero shares?

Is now the time to buy this popular share? Let's see what brokers are saying.

Read more »

Hologram of a man next to a human robot, symbolising artificial intelligence.
Technology Shares

Appen share price rockets 18% on guidance update

Let's see what is getting investors excited on Friday.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

Up 50% in a year, are Xero shares a buy after Thursday's earnings results?

ASX investors reacted positively to Xero’s full-year earnings results on Thursday. Now what?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Earnings Results

Xero share price higher despite FY25 earnings miss

The cloud accounting platform provider reported strong top line growth but its earnings fell short of expectations.

Read more »

Man pointing at a blue rising share price graph.
Technology Shares

Up 57% in a year, why this ASX 200 tech stock could keep charging higher into 2026

A leading expert foresees a bright outlook for this fast-rising ASX 200 tech stock.

Read more »

Man sitting at poker machine celebrates a win by raising his arms straight up in the air.
Technology Shares

Goldman Sachs says this beaten down ASX 200 share can rise 19%

Let's see why the broker is still bullish on this growth stock.

Read more »

Hand with AI in capital letters and AI-related digital icons.
Technology Shares

Google search volume declines for first time in 22 years. Have AI powered tools taken over?

It could be good news for these two AI-related ASX stocks.

Read more »